worldwiki
informational

What is the difference between adult stem cells and embryonic stem cells?

Published Sep 18, 2026Updated Sep 19, 2026Last verified Sep 18, 2026Requests recorded in this site’s own server logs, with the crawler identity checked by reverse DNS or IP range.Google5OpenAI1Yandex1First collected Sep 18, 2026Recent requestsGoogleSep 20, 2026OpenAISep 20, 2026GoogleSep 19, 2026GoogleSep 19, 2026GoogleSep 19, 2026GoogleSep 18, 2026YandexSep 18, 2026
Request a correction
LanguagesEnglishWritten for this market; it is not a translation of another page.
Quick answer

The main difference is potency. Embryonic stem cells are pluripotent and can give rise to nearly all of the body's cell types. Adult stem cells are generally multipotent or unipotent, so they make only the cell types of their own tissue. Adult stem cells come from mature tissues such as bone marrow, skin or the cornea. Blood stem cell transplantation, which uses adult stem cells, is an established therapy.

69 words12 sources

Answer

Adult stem cells are tissue-restricted and range from multipotent to unipotent [2]. Blood stem cell transplantation has been used for more than 50 years [12].

Sources

  1. journalAdult Stem Cells – Stem Cells and the Future of Regenerative Medicine — National Research Council and Institute of Medicine (National Academies Press, via NCBI Bookshelf) · accessed Sep 20, 2026 · Evidence page
  2. journalMultipotent to Pluripotent Properties of Adult Stem Cells — Stem Cells International (Hindawi), via PubMed Central · accessed Sep 20, 2026 · Evidence page
  3. journalAdult stem cells and their trans-differentiation potential—perspectives and therapeutic applications — Journal of Molecular Medicine (Hombach-Klonisch et al.), via PubMed Central · accessed Sep 20, 2026 · Evidence page
  4. academicMinimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement — Cytotherapy 8(4):315-317 (Dominici et al.) · accessed Sep 20, 2026 · Evidence page
  5. journalContinuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors — Haematologica (Atsuta et al.) · accessed Sep 20, 2026 · Evidence page
  6. journalOne and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors (Niederwieser D, et al., Haematologica 107(5):1045-1053) — Haematologica · accessed Sep 20, 2026 · Evidence page
  7. governmentFDA approves remestemcel-L-rknd for steroid-refractory acute graft versus host disease in pediatric patients — U.S. Food and Drug Administration · accessed Sep 19, 2026 · Evidence page
  8. governmentConsumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes — U.S. Food and Drug Administration · accessed Sep 19, 2026 · Evidence page
  9. governmentPatient and Consumer Warning about Potential Serious Risks of Harm following Use of Unapproved Products from Human Cells or Tissues — U.S. Food and Drug Administration · accessed Sep 19, 2026 · Evidence page
  10. governmentFirst stem-cell therapy recommended for approval in EU (press release) — European Medicines Agency · accessed Sep 20, 2026 · Evidence page
  11. governmentHoloclar – EPAR — European Medicines Agency · accessed Sep 20, 2026 · Evidence page
  12. organizationStem Cell Resources for Patients — International Society for Stem Cell Research (ISSCR) · accessed Sep 20, 2026 · Evidence page